Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Medivation/Astellas Confident Xtandi Data Will PREVAIL With Urologists

Oct 28 2013

• By Cathy Kelly

Related Content

FDA Approves <em>Zytiga</em> In Earlier Prostate Cancer Setting

Dec 11 2012

Can <em>Zytiga </em>Prevail In Pre-Chemo Prostate Cancer Without Proof Of Survival Benefit?

Dec 17 2012

Medivation/Astellas’ <em>Xtandi</em> A Tough Rival For J&J’s <em>Zytiga</em>

Sep 10 2012

Related Companies

Medivation, Inc.

Astellas Pharma, Inc.

Sanofi

Johnson & Johnson

AstraZeneca PLC

Additional Topics

Clinical Trials BioPharmaceutical

More from Clinical Trials

More from R&D

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window